Background: Lifestyle and dietary advice typically precedes or accompanies the prescription of statin medications. However, evidence for adherence to this advice is sparse. The objective was to compare saturated fat intake, exercise, alcohol consumption and smoking between statin users and non-users in Australia. Methods: Data were analysed for 4614 participants aged 37 years in the Australian Diabetes, Obesity and Lifestyle study in 2011-2012. Statin use, smoking status and physical activity were self-reported. Saturated fat and alcohol intake were measured via a food frequency questionnaire. Multinomial logistic regression was used to compute adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between statin use and the four lifestyle factors. All models were adjusted for age, sex, education, number of general practitioner visits, body mass index, hypertension, diabetes and prior cardiovascular diseases. Results: In total 1108 (24%) participants used a statin. Statin users were 29% less likely to be within the highest quartile versus the lowest quartile of daily saturated fat intake compared to non-users (OR 0.71, 95% CI 0.54-0.94). There were no statistically significant associations between statin use and smoking, physical activity or alcohol consumption. Conclusions: Smoking status, alcohol consumption and exercise level did not differ between users and non-users of statins. However, statin users were less likely to consume high levels of saturated fat than non-users. We found no evidence that people took statins to compensate for a poor diet or lifestyle.
Introduction
Lifestyle and dietary modifications are the cornerstone of primary and secondary prevention of cardiovascular disease (CVD). Smoking cessation, low-moderate alcohol consumption, exercise and reduction in saturated fat intake reduce CVD risk. [1] [2] [3] [4] Guidelines recommend that lifestyle and dietary advice should precede or accompany the prescription of statin medications. 5, 6 However, as lifestyle and dietary modifications can be challenging to implement and maintain, guidelines may not be followed. 7, 8 Meta-analyses have demonstrated the effectiveness of statin treatment in reducing cardiovascular-related mortality and morbidity. 9, 10 The prescribing of statins has increased rapidly in Australia, Europe and the USA.
The prevalence of statin use increased from 17% in 2001 to 35% in 2012 among Australian veterans. 11 In the UK, the threshold for prescribing statins for primary prevention has been lowered from a 20% 10-year CVD risk to a 10% 10-year CVD risk. 12 New US guidelines suggest that statins should be prescribed to those with a 7.5% 10-year risk. 13 This corresponds to an estimated additional 13 million individuals being eligible for statin therapy. 13 It is not known whether statin use complements or substitutes a healthy lifestyle and diet. Patients may perceive that statins represent an alternative path to health benefits, 7 and the prescribing of statins may diminish clinicians' focus on CVD risk reduction via lifestyle and diet.
14 Previous studies comparing lifestyle factors between statin users and non-users have reported inconsistent findings. A Swedish study in 2012 reported that statin users were more likely to understand the importance of CVD risk reduction and were more likely to undertake lifestyle modifications. 15 However, more recent US studies have reported that statin users had lower exercise levels, 16 and greater increases in caloric and fat intake than non-users of statins. 17 These findings may be explained by risk compensation, in which people receiving a particular risk-lowering intervention are more likely to engage in risky behaviours. 18 Alternatively, statins may cause muscular pain that discourages exercise or be prescribed to patients with comorbidities that prevent participation in exercise. 16, 19 No population-based studies on the association between statin use and lifestyle or diet have been conducted in Australia. The objective of this study was to compare saturated fat intake, exercise, alcohol consumption and smoking between statin users and non-users in Australia.
Methods

Study design, setting and participants
The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) is a 12-year longitudinal population-based study. The baseline assessment was conducted in 1999-2000, during which a total of 11,247 people aged 25 years and older in 42 randomly selected urban and rural areas across seven states and territories consented to participate. Data on clinical, demographic, health and lifestyle factors were collected using a series of interviewer and self-administered questionnaires, with biomedical examinations conducted at local testing sites. Two follow-up examinations were conducted. The first follow-up took place in 2004-2005 (wave 2) and 6400 (59.3%) eligible participants from baseline participated. The second follow-up took place in 2011-2012 (wave 3) and 4614 (44.6%) eligible participants from the baseline assessment participated. The full study methods and response rate for the baseline survey have been described previously. 20 The current study was a cross-sectional analysis of data collected in 2011-2012 (wave 3).
Definitions and measurements
Medication use was self-reported by participants using a self-administered questionnaire. All medications were coded using the Anatomical Therapeutic Chemical (ATC) classification recommended by the World Health Organization (WHO). 18, 21 Statin users were defined as those who took a statin (ATC codes C10AA, C10BA, C10BX) for at least 2 weeks within the last 3 months.
The lifestyle factors measured as outcomes were smoking status, alcohol consumption, exercise level and saturated fat intake. Smoking status was measured via self-administered questionnaire and participants were categorised as current smokers, former smokers or never smokers. Current smokers included those who smoked on a daily basis, former smokers included those who smoked less than daily in the past 3 months, and never smokers were defined as those who smoked less than 100 cigarettes during their lifetime. This categorisation was consistent with previous research. 20 Physical activity was measured via a self-administered questionnaire using questions regarding time spent doing vigorous and moderate physical activity in the previous week. Physical activity was categorised consistent with previous research, 20 into sedentary (no participation in physical activity in the previous week), insufficiently active (>0-149 minutes of moderate activity in the previous week and >0-74 minutes of vigorous activity in the previous week) and sufficiently active (150 minutes of moderate-intensity or 75 minutes of vigorous activity in the previous week).
Saturated fat intake as grams per day was calculated using a self-administered food frequency questionnaire (FFQ), recalling intake over the previous 12 months. 20 Saturated fat intake was expressed as a percentage of total daily energy intake and categorised into quartiles. 22 Daily alcohol consumption was obtained via the FFQ and expressed in grams of ethanol per day. Daily alcohol consumption was categorised into no drinking (0 g), low-moderate drinking (>0-20 g), heavy drinking (>20-40 g) and excessive drinking (>40 g), where 10 g of alcohol is equivalent to 1 unit of alcohol. 4, 23 Covariates Age, sex, education level, number of general practitioner (GP) visits, body mass index (BMI), hypertension, diabetes and prior CVD were considered as covariates. Participant's education level was assessed at baseline and wave 2. If a participant reported a higher level of education at wave 2 then this level was used to replace their baseline response. Participants were categorised into having not attended school, some primary or secondary education including completion of secondary education versus having some education above secondary level. The number of GP visits within the last 3 months was obtained via an interviewer administered questionnaire. This variable was categorised into no visits, one visit, two visits and three or more visits. BMI (kg/m 2 ) was calculated during biomedical examinations and was categorised into normal (BMI <25.0), overweight (BMI 25.0-29.9) and obese (BMI 30.0). 24 Hypertension was defined based on blood pressure (BP) measurement and participant's self-report of medications used for treating hypertension. BP measurements were completed in a seated position using an automated BP monitor which was regularly calibrated (Dinamap Pro-series Monitor Model DP 101-NIBP, pulse and recorder; GE Medical Systems Information Technologies, Milwaukee, USA). Three measurements were taken at 30-second intervals. The mean of the first two measurements was taken unless the difference between the first and second measurement was greater than 10 mmHg. In this case the third measurement was considered, and the mean of the two closest readings was used. Hypertension was categorised as normotension (BP <140/90 mmHg and no medication use for hypertension), untreated hypertension (BP 140/90 mmHg and no medication use for hypertension) and treated hypertension (those who reported taking medications for hypertension). 25 Participants were considered to have diabetes if their fasting blood glucose was 7.0 mmol/L, 2-hour blood glucose was 11.1 mmol/L, or they reported using medications for diabetes (ATC code A10). 20, 26 Participants were regarded to have prior CVD if they self-reported having had angina, stroke or myocardial infarction (MI) at baseline, had a MI, stroke, coronary artery angioplasty surgery or coronary artery bypass surgery between baseline and wave 3, or reported using nitrates (ATC code C10DA) at wave 3.
Statistical analysis
Demographic and clinical characteristics of statin users and non-users were presented as proportions or means with standard deviations. The association between statin use and each lifestyle factor was examined using multinomial logistic regression. One regression model was computed for each of the four lifestyle factors. For each model, statin use (yes/no) was the primary exposure variable and age, sex, education level, hypertension, diabetes, BMI, number of GP visits in the previous 3 months, prior CVD and lifestyle factors other than the outcome were treated as covariates. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The analyses were performed using SAS (version 9.4; Cary, NC, USA).
To investigate the representativeness of participants at wave 3 of the original cohort at baseline we compared baseline characteristics between those participants who attended and those who did not attend the wave 3 examination. The proportion of women was similar between the groups, but participants who attended wave 3 were younger (mean age 48.9 years vs. 53.7 years). Attendees had on average fewer GP visits during the previous 12 months, the proportion of people with hypertension, diabetes and prior cardiovascular disease were lower and they had a lower baseline prevalence of lipid-lowering medicine use than those who did not attend.
Results
A total of 1108 of the 4614 participants (24%) in wave 3 used a statin. The mean age of statin users was 67.8 years compared to 58.6 years in non-users. Half of all statin users were men (51.3%) compared to only 42.6% of non-users. The prevalence of prior CVD, diabetes and treated hypertension was higher among statin users compared to non-users (corresponding comparisons of 21.7% vs. 2.7%, 25.2% vs. 5.1% and 57.2 vs. 21.3%, respectively). The characteristics of statin users and non-users are summarised in Table 1 . The prevalence of current smoking was lower in statin users than non-users (3.8% in statin users, 6.3% in non-users).
After adjustment for the covariates, statin use was not associated with being in the second (OR 1.05; 95% CI 0.82-1.35) or third (OR 0.80; 95% CI 0.62-1.04) quartile versus the lowest quartile of daily saturated fat intake (Table 2) . However, statin users were 29% less likely to be within the highest quartile versus the lowest quartile of daily saturated fat intake compared to non-users (OR 0.71, 95% CI 0.54-0.94). There were no statistically significant associations between statin use and smoking, physical activity or alcohol consumption.
Discussion
The main finding of this study was that statin users were 29% less likely consume high amounts of saturated fat as a percentage of total daily energy intake compared to non-users. Statin users and non-users were equally likely to consume high levels of alcohol and have a sedentary lifestyle. Similarly, there was no difference in current smoking and former smoking, when adjusting for clinically relevant covariates.
Our study found that statin users had a lower saturated fat intake compared to non-users. This is consistent with a previous study in Sweden, which found that statin users had better dietary habits compared to non-users. 15 Statin users may be more exposed to dietary information from their healthcare professionals. However, another US study showed that caloric and fat intake among statin users increased by 9.6% over a 10-year period among the US general population, while in non-users the intake remained constant over the same period. 17 This suggests that the attitudes towards dietary recommendations may change over time, in which people prescribed statins increasingly accept statins as a compensatory measure for an unhealthy diet. It is unclear whether the lifestyle behaviours of statin users in the USA are generalisable to Australia. Unlike the US repeated cross-sectional study, our study was a single cross-sectional study and, therefore, we were unable to assess whether lifestyle factors changed over time. Further longitudinal research is needed to determine whether possible lifestyle modifications among statin users in Australia are sustained over time.
Furthermore, the inconsistencies between Swedish, US and Australian research suggest that statin users in these countries may have a different lifestyle profile. 15, 17 The accessibility to statin therapy might also be different in these countries. This is an important consideration for extrapolating the findings of research that has investigated the cardiovascular outcomes of statin users in these countries.
In the present study, smoking status did not differ between statin users and non-users in the adjusted analyses, with low rates of current smokers in both groups (3.8% and 6.3%, respectively). The finding is consistent with previous literature in which people have been observed to continue smoking despite known negative health effects. 27 Barriers associated with smoking cessation range from reliance on smoking for stress management, not seeking adequate professional help, 28 fear of weight gain and concerns regarding costs, particularly in vulnerable groups. 27 Moreover, a significant proportion of non-smokers with coronary heart disease who are treated with statins are exposed to passive smoking, which may hinder smoking cessation. 29, 30 One study found that GPs only initiated discussion regarding smoking cessation when patients presented with smoking-related symptoms. 31 Physicians perceived discussions were too time consuming. Lack of support from physicians and lack of patients' awareness of cardiovascular risk factors may be a barrier to healthy lifestyle changes. 32, 33 Moreover, a review of several landmark trials observed that smoking diminishes the benefits of statins in reducing CVD risk. 34 The review found that the risk of a CVD event in untreated non-smokers was of the same magnitude as the risk of smokers taking statins. Never smoker <100 cigarettes during life, former smoker less than daily for at least 3 months, current smoker at least daily.
a Education level was assessed at baseline and at wave 2. b GP visits were calculated over a period of 3 months. One unit of alcohol equates to 10 g of alcohol (specific to Australia). d Daily saturated fat intake calculated as a percentage of total energy intake.
Therefore, although the prevalence of current smoking in the present study was low, the importance of smoking cessation may need to be re-iterated to smokers who are prescribed statins. This study showed no association between statin use and physical activity. It is possible that statin users may have exercised less than non-users prior to statin initiation or that statin users may have conditions that inhibit their ability to exercise. Once prescribed statins, people may have increased their exercise levels to the same level as non-users; however, further longitudinal research is needed. Previous studies have found that statin users undertake less exercise than non-users. 16 One possible explanation for these findings may be due to statin-related side effects ranging from rare cases of rhabdomyolysis to more common muscle weakness and muscle pain. 35 A study in France found, that among 7924 patients taking statins, 11% experienced muscle symptoms, 4% had symptoms severe enough to interfere with daily activities and 0.4% were confined to bed with their symptoms. 36 No difference in alcohol consumption between statin users and non-users was found. There is no consensus on the effect of statin use on alcohol consumption as previous studies have produced conflicting results. A recent study reported that statin use was associated with a 15% increase in moderate alcohol use among men, 37 while another study has reported that the proportion of statin users is higher among non-drinkers than heavy drinkers. 38 Only 4% of GPs surveyed reported asking patients about their alcohol consumption 'all of the time', 39 which may reduce patient awareness about the effects of alcohol. Low-moderate alcohol consumption of up to two standard drinks daily has been shown to be the most beneficial in reducing CVD risk. 40 Despite this, non-drinkers are not advised to start drinking to reduce their CVD risk. 41 A metaanalysis of brief interventions in primary care aimed at reducing alcohol consumption demonstrated a decline of 38 g of ethanol per week following intervention. 42 However, this intervention may be underutilised due to healthcare workers having insufficient time or lack of training, 39 which may have implications for excessive drinkers, who could potentially benefit from such a service.
The intensity of how clinicians recommend lifestyle modifications to prevent CVD may have been linked to participants' total cardiovascular risk. It is possible that those prescribed and persisting with statins were more engaged in managing a range of cardiovascular risk factors, including smoking, diet, lifestyle and diabetes as they would be at elevated risk of CVD. We are unable to determine to what extent statin users and non-users may have received different advice from their clinicians, and to what extent this advice was followed by patients. Our study was cross-sectional in design and, therefore, it was not possible to determine whether statin users had poorer smoking, dietary and lifestyle behaviours prior to statin initiation.
Strengths and limitations
This study has several strengths. The data consisted of a random sample of more than 4600 participants from urban, suburban and regional areas across Australia. The data were collected in 2011-2012 and reflect relatively recent Australian prescribing and lifestyle patterns. To ensure a representative sample stratified cluster sampling was employed. Multivariate analyses were performed to accommodate potential confounding factors.
There are some limitations to the present study. Selfreporting of statin use and lifestyle factors may have caused some participants to report their statin use or lifestyle incorrectly. This may have resulted in over or under-estimation of the effect of statin use or the covariates. The participation rate at wave 3 was 4614 of the 11,247 who consented to participate at baseline. Although we utilised the most recent data collected, participants at wave 3 might not be a representative sample of those at baseline. We compared the baseline characteristics of those who participated to those who did not participate at wave 3. These results showed that those who attended at wave 3 compared to those who did not were younger and had fewer cardiovascular risk factors at baseline. However, the associations between statin use and lifestyle behaviours among the wave 3 cohort are still likely to be valid. Missing data in this analysis were excluded. Although the number of missing values per variable was relatively small (<12%), this might have led to partially biased estimates in our multivariate analyses. For example, if the food frequency diary was not completed for those who were excessive alcohol consumers or had high saturated fat intake, this might have caused underestimation of these parameters. The cross-sectional design did not allow an assessment of causality related to statin use and lifestyle factors. This also means that we did not have information on statin initiation and how lifestyle factors may have changed over time.
Conclusion
Statin users had lower saturated fat intake than nonusers. However, there was no difference in smoking status, exercise levels or alcohol consumption between statin users and non-users after adjusting for clinically important covariates. We found no evidence that people take statins to compensate a healthy lifestyle. Our results suggest that statin users in Australia may have a different lifestyle profile to statin users in the USA and Sweden. Longitudinal studies are needed to determine whether possible lifestyle modifications among statin users in Australia are sustained over time.
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